$610 Million is the total value of TCG Crossover Management, LLC's 22 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 18.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Sell | IVERIC BIO INC | $96,336,933 | -23.0% | 2,448,829 | -52.4% | 15.80% | -35.2% |
| GERN | Buy | GERON CORP | $75,723,191 | +96.4% | 23,589,779 | +32.8% | 12.42% | +65.3% |
| COGT | Buy | COGENT BIOSCIENCES INC | $66,671,537 | +70.2% | 5,631,042 | +55.1% | 10.93% | +43.2% |
| VECT | VECTIVBIO HOLDING AG | $52,931,200 | +99.8% | 3,113,600 | 0.0% | 8.68% | +68.1% | |
| AVTE | Buy | AEROVATE THERAPEUTICS INC | $37,751,849 | +73.1% | 2,201,274 | +103.6% | 6.19% | +45.6% |
| New | ICOSAVAC, INC | $36,777,781 | – | 3,703,704 | +100.0% | 6.03% | – | |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $34,630,827 | -4.6% | 149,917 | 0.0% | 5.68% | -19.8% | |
| TYRA BIOSCIENCES INC | $33,874,424 | +6.0% | 1,989,103 | 0.0% | 5.56% | -10.8% | ||
| KALV | KALVISTA PHARMACEUTICALS, INC | $30,559,455 | +14.5% | 3,395,495 | 0.0% | 5.01% | -3.7% | |
| VENTYX BIOSCIENCES, INC | $26,755,747 | -2.1% | 815,724 | 0.0% | 4.39% | -17.6% | ||
| DYN | DYNE THERAPEUTICS, INC | $18,564,188 | -2.3% | 1,650,150 | 0.0% | 3.04% | -17.8% | |
| KURA | KURA ONCOLOGY INC | $15,062,132 | -13.5% | 1,423,642 | 0.0% | 2.47% | -27.2% | |
| STRUCTURE THERAPEUTICS INCadrs | $14,549,500 | +74.7% | 350,000 | 0.0% | 2.39% | +47.0% | ||
| IMVT | IMMUNOVANT, INC | $12,422,561 | +22.3% | 654,853 | 0.0% | 2.04% | +2.9% | |
| SLN | SILENCE THERAPEUTICS PLCadrs | $11,576,813 | -11.3% | 2,104,875 | 0.0% | 1.90% | -25.4% | |
| New | AN2 Therapeutics, Inc. | $10,959,220 | – | 1,289,320 | +100.0% | 1.80% | – | |
| ENTRADA THERAPEUTICS INC | $8,856,219 | +4.4% | 584,955 | 0.0% | 1.45% | -12.2% | ||
| MRUS | MERUS BV | $7,899,000 | +43.1% | 300,000 | 0.0% | 1.30% | +20.4% | |
| CABA | CABALETTA BIO, INC | $6,284,523 | +56.1% | 486,795 | 0.0% | 1.03% | +31.3% | |
| ACRS | ACLARIS THERAPEUTICS INC | $5,494,430 | +28.2% | 529,839 | 0.0% | 0.90% | +7.8% | |
| CCCC | Buy | C4 THERAPEUTICS, INC. | $3,510,579 | -10.6% | 1,276,574 | +2.1% | 0.58% | -24.7% |
| ALPN | ALPINE IMMUNE SCIENCES INC | $2,601,549 | +33.2% | 253,069 | 0.0% | 0.43% | +12.1% | |
| VRDN | Exit | VIRIDIAN THERAPEUTICS, INC | $0 | – | -663,610 | -100.0% | -3.29% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -3,048,257 | -100.0% | -5.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.